Archives for September 28, 2004

← 2004

Report identifies increasing outsourcing by pharma

A new report into pharmaceutical R&D has identified an emerging trend favouring outsourcing of discovery research, clinical trials and formulation manufacturing, providing pressure relief from consistent, high-growth financial returns faced by the...

CompleGen deal allows compound library access

A collaboration between CompleGen and DuPont is set to industrialize the pre-clinical drug development process and reduce the time to bring a drug to market. Under terms, CompleGen will gain access to a chemical library consisting of compounds...

Mass production opportunities open up for natural sweetener

Competition in the sweeteners market could move up a gear in the near future as Japanese scientists harness production capacity for the taste-altering protein miraculin that makes sour foods taste sweet,reports Lindsey Partos.

Evidence builds for new cancer drug target

Researchers in the US have recognised one of the key functions of the c-myb gene, which leukaemia cells depend on for proliferation, is the formation of white blood cells. The discovery is sure to position the gene as a potential cancer drug target...

Molecular switch allows mobile cancer cells

A molecular 'switch' allowing cancer cells to detach themselves from the host of other cancer cells and move away to a different parts of the body has been discovered Researchers believe this molecular step is a viable target of which drugs designed...

Irish pharma back with a bang in July

Ireland's pharmaceutical industry saw a return to strong growth in July, after a lengthy period in which the prevailing wisdom was that the sector had plateaued.

Bulk drug centre planned in India

The port city of Visakhapatnam in India is to form a 'pharma city' to house bulk drug manufacturers, according to local news reports.

CMO gets US FDA approval

Medivative Technologies, a contract manufacturing and process engineering services supplier to the life sciences and medical device industries, has just been cleared for operations by the US Food and Drug Administration (FDA).